Format

Send to

Choose Destination
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Oct;23(5):1231-4. doi: 10.7534/j.issn.1009-2137.2015.05.002.

[Immunophenotypic Analysis of Patients with CD56⁺ Acute Myeloid Leukemia].

[Article in Chinese]

Author information

1
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital), Nanjing 210029, Jiangsu Province, China.
2
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital), Nanjing 210029, Jiangsu Province, China. E-mail: wuyujie123456@163.com.

Abstract

OBJECTIVE:

To explore the immunophenotype characteristics of newly diagnosed patients with CD56⁺ acute myeloid leukemia (AML).

METHODS:

Combining with cytomorphology, four-color flow cytometry was used to analyze the immunophenotype of 342 AML patients with CD56⁺ or CD56⁻.

RESULTS:

In 342 AML patients, the CD56⁺ expression was found in 83 AML patients who accounted for 24.27% and included 10 cases of M1, 45 cases of M2, 5 cases of M3, 6 cases of M6 and 17 cases of M5. The statistical analysis showed that there was statistical difference between CD56⁺ and CD11b⁺ patients (P < 0.05), but there was no statistical difference between CD56⁺ and HLA-DR, CD34, CD38, CD13, CD33, CD15, CD117, CD14, CD64, CD2, CD7, CD5, CD3, CD4, CD10, CD19, CD20, CD22 (P > 0.05).

CONCLUSION:

AML with only CD56 positive always has poor prognosis, thus the prognosis of patients with CD56⁺ AML accompanied by other antigens still needs more research.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center